Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Cash & Current Investments (2016 - 2025)

Ligand Pharmaceuticals' Cash & Current Investments history spans 16 years, with the latest figure at $139.4 million for Q3 2025.

  • For Q3 2025, Cash & Current Investments rose 119.08% year-over-year to $139.4 million; the TTM value through Dec 2025 reached $1.1 billion, up 313.41%, while the annual FY2024 figure was $256.2 million, 1015.99% up from the prior year.
  • Cash & Current Investments for Q3 2025 was $139.4 million at Ligand Pharmaceuticals, down from $245.0 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $341.1 million in Q4 2021 and bottomed at $5.3 million in Q2 2022.
  • The 5-year median for Cash & Current Investments is $63.6 million (2024), against an average of $127.0 million.
  • The largest annual shift saw Cash & Current Investments tumbled 95.58% in 2022 before it soared 1785.31% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $341.1 million in 2021, then plummeted by 37.89% to $211.9 million in 2022, then plummeted by 89.17% to $23.0 million in 2023, then surged by 1015.99% to $256.2 million in 2024, then crashed by 45.59% to $139.4 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Cash & Current Investments are $139.4 million (Q3 2025), $245.0 million (Q2 2025), and $208.9 million (Q1 2025).